Cell-free DNA analysis reveals POLR1D -mediated resistance to bevacizumab in colorectal cancer

ConclusionsNon-invasive analyses of cell-free DNA from patients undergoing treatment with bevacizumab enabled the tracking of evolving tumor genomes and helped identify a recurrent focal SCNA of clinical relevance. Here, we describe a novel resistance mechanism against a widely applied treatment in patients with mCRC which will impact the clinical management of patients.

Source: Genome Medicine - February 21, 2020 Category: Genetics & Stem Cells Source Type: research